VALENTIS COMPLETES PATIENT DOSING FOR TRIAL OF VLTS 934

Valentis has completed the dosing on schedule in its VLTS 934 Phase IIb trial for the treatment of patients suffering with peripheral arterial disease (PAD).

The 140-patient, randomized, double-blind and placebo-controlled trial began in March 2005. It is a multicenter trial beingconducted throughout the U.S. Patients with PAD, specifically intermittent claudication, which is leg pain during walking, were randomized to receive either VLTS 934 or a saline placebo. The primary endpoint of the trial is improvement in exercise tolerance 90 days after treatment.